Gilead posts higher profit as HIV sales rise, helped by prevention drugs

Core Insights - Gilead Sciences reported a 4% increase in HIV drug sales, reaching $5.3 billion in the third quarter, which includes $39 million from its new prevention drug Yeztugo, contributing to profits exceeding Wall Street expectations [1] Sales Performance - The total sales of Gilead's HIV drugs rose to $5.3 billion in Q3, marking a 4% increase compared to previous periods [1] - The new prevention drug Yeztugo generated $39 million in sales, indicating a positive reception in the market [1] Profitability - The increase in HIV drug sales and the introduction of Yeztugo helped Gilead Sciences achieve profits that surpassed Wall Street's forecasts [1]